AstraZeneca (AZN) Posts Light Q4 EPS Results; Revs Top Views
AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.16, $0.40 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $8.66 billion versus the consensus estimate of $8.59 billion.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Basilea participates in public-private collaboration to tackle antibiotic resistance
- UPDATE: Stein Mart (SMRT) Reports Q1 Adj-EPS of 32c, Beats by 2c
- UPDATE: Auriga Starts Teva Pharma (TEVA) at Hold; Sidelined Until New CEO Is Convincing
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
